Nirsevimab Library
This is a collection of current resources related to Nirsevimab.
Parent Perspectives on Nirsevimab for Their Newborn
2024
· Yale School of Medicine,
· Yale University
This article explores how parents feel about using nirsevimab for their newborns. Nirsevimab is a medicine that helps protect babies from RSV, a common virus …
Ask aRCie
RSV Prevention in Infants: Promising Products, But at What Cost?
This commentary is related to two studies on the cost-effectiveness of maternal vaccination and nirsevimab for infants for the prevention of respiratory syncytial virus (RSV). …
Respiratory Viruses Vaccine Recommendations
This site provides vaccine recommendations for respiratory viruses like COVID-19, flu, and RSV. It describes who should get vaccinated and when. Everyone 6 months and …
Respiratory Syncytial Virus (RSV): Advisory Committee on Immunization Practices (ACIP) Recommendations
2024
· Johns Hopkins University
The Advisory Committee on Immunization Practices (ACIP) provides guidelines for preventing Respiratory Syncytial Virus (RSV). Infants up to 8 months should get a dose of …
Estimates: Nirsevimab 89% Effective Against RSV in Kids, 93% Against Hospitalization
2024
· University of Minnesota
This news brief describes the effectiveness of nirsevimab, a monoclonal antibody drug, in protecting children under 5 from RSV. The drug is 89% effective against …
Studies Show More Promising Results for RSV Drug Nirsevimab
2024
· University of Minnesota
This blog post describes two studies showing that the RSV drug nirsevimab is effective in protecting infants from respiratory syncytial virus. The first study found …
Ask the Experts: RSV (Respiratory Syncytial Virus)
2024
· Immunize.org
This Q&A explains RSV (Respiratory Syncytial Virus), a common virus causing cold-like symptoms. It can be severe in infants and older adults. There are no …
New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy
This article discusses new ways to protect babies from RSV, a virus causing lung infections. Two methods were approved in 2023: one uses a long-lasting …
Impact of Nirsevimab Prophylaxis on Paediatric Respiratory Syncytial Virus (RSV)-Related Hospitalisations During the Initial 2023/24 Season in Luxembourg
2024
· European Centre for Disease Prevention and Control (ECDC),
· European Centre for Disease Prevention and Control (ECDC),
· Centre Hospitalier de Luxembourg
This study examines the impact of nirsevimab, a new antibody, on reducing RSV-related hospitalizations in Luxembourg during the 2023/24 season. After its introduction, neonatal coverage …
Does Nirsevimab Prevent Lower Respiratory Infections Caused by Respiratory Syncytial Virus?
2024
· University of Virginia
This study examines nirsevimab, a monoclonal antibody that helps prevent respiratory syncytial virus (RSV) infections in infants. It found that one injection of nirsevimab significantly …